Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation
Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors
J Clin Virol
Molecular Weight: 352
and has weaker activity against monoamine oxidase proteins MAO-A and MAO-B with IC50 ~0
(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 EZH2 inhibitor efficacy in non-Hodgkin'sMutations, CAS No. 103404 90 6, in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R) enantiomer of 2 hydroxyglutarate [(R) 2 HG]. Elucidation of the role of IDH mutations and (R) 2 HG in leukemogenesis has been hampered by a lack of appropriate cell based models. It has been recently reported that a canonical IDH1 mutant, IDH1
US$ 141.26
US$ 264.00
US$ 163.90
US$ 138.60
US$ 243.09
US$ 396.00
US$ 188.90
US$ 126.47
US$ 137.54
US$ 188.90
US$ 137.54